Left ventricular assist devices: a kidney's perspective

Verfasser / Beitragende:
[T. Tromp, N. de Jonge, J. Joles]
Ort, Verlag, Jahr:
2015
Enthalten in:
Heart Failure Reviews, 20/4(2015-07-01), 519-532
Format:
Artikel (online)
ID: 605478929
LEADER caa a22 4500
001 605478929
003 CHVBK
005 20210128100407.0
007 cr unu---uuuuu
008 210128e20150701xx s 000 0 eng
024 7 0 |a 10.1007/s10741-015-9481-z  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10741-015-9481-z 
245 0 0 |a Left ventricular assist devices: a kidney's perspective  |h [Elektronische Daten]  |c [T. Tromp, N. de Jonge, J. Joles] 
520 3 |a The left ventricular assist device (LVAD) has become an established treatment option for patients with refractory heart failure. Many of these patients experience chronic kidney disease (CKD) due to chronic cardiorenal syndrome type II, which is often alleviated quickly following LVAD implantation. Nevertheless, reversibility of CKD remains difficult to predict. Interestingly, initial recovery of GFR appears to be transient, being followed by gradual but significant late decline. Nevertheless, GFR often remains elevated compared to preimplant status. Larger GFR increases are followed by a proportionally larger late decline. Several explanations for this gradual decline in renal function after LVAD therapy have been proposed, yet a definitive answer remains elusive. Mortality predictors of LVAD implantation are the occurrence of either postimplantation acute kidney injury (AKI) or preimplant CKD. However, patient outcomes continue to improve as LVAD therapy becomes more widespread, and adverse events including AKI appear to decline. In light of a growing destination therapy population, it is important to understand the cumulative effects of long-term LVAD support on kidney function. Additional research and passage of time are required to further unravel the intricate relationships between the LVAD and the kidney. 
540 |a The Author(s), 2015 
690 7 |a Left ventricular assist device  |2 nationallicence 
690 7 |a Renal function  |2 nationallicence 
690 7 |a Cardiorenal syndrome  |2 nationallicence 
690 7 |a Chronic kidney disease  |2 nationallicence 
690 7 |a Acute kidney injury  |2 nationallicence 
690 7 |a Mechanical circulatory support  |2 nationallicence 
700 1 |a Tromp  |D T.  |u University Medical Center Utrecht, POB 85500, 3508 GA, Utrecht, The Netherlands  |4 aut 
700 1 |a de Jonge  |D N.  |u Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands  |4 aut 
700 1 |a Joles  |D J.  |u Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands  |4 aut 
773 0 |t Heart Failure Reviews  |d Springer US; http://www.springer-ny.com  |g 20/4(2015-07-01), 519-532  |x 1382-4147  |q 20:4<519  |1 2015  |2 20  |o 10741 
856 4 0 |u https://doi.org/10.1007/s10741-015-9481-z  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10741-015-9481-z  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tromp  |D T.  |u University Medical Center Utrecht, POB 85500, 3508 GA, Utrecht, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a de Jonge  |D N.  |u Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Joles  |D J.  |u Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Heart Failure Reviews  |d Springer US; http://www.springer-ny.com  |g 20/4(2015-07-01), 519-532  |x 1382-4147  |q 20:4<519  |1 2015  |2 20  |o 10741